StemCells Inc news

   Watch this stock
Showing stories 11 - 20 of about 80   

Articles published

STEM 1.17 +0.01 (1.29%)
price chart
StemCells Starts Phase II Cervical Spinal Cord Injury Study
StemCells Inc. (STEM) announced that it has commenced a phase II proof-of-concept study, Pathway, which will use the company's proprietary human neural system stem cells (HuCNS-SC) platform for treating patients suffering from cervical spinal cord ...
Stock Summary Report: Apple Inc. (NASDAQ:AAPL), Cerus Corporation ...
StemCells Inc (NASDAQ:STEM), the developer of cell-based therapies for the treatment of disorders of the central nervous system said it has initiated its Pathway Study, a Phase II proof-of-concept clinical trial using its HuCNS-SC platform of human ...
Related articles »  
StemCells Starts Phase II Cervical Spinal Cord Injury Study - Analyst Blog
StemCells Inc. ( STEM ) announced that it has commenced a phase II proof-of-concept study, Pathway, which will use the company's proprietary human neural system stem cells (HuCNS-SC) platform for treating patients suffering from cervical spinal cord ...
Related articles »  
UCSD, other stem cell clinics get millions
But CIRM's previous president, Alan Trounson, caused more controversy when he joined the board of CIRM-funded Stemcells Inc, just one week after departing the agency. CIRM President Randy Mills, who replaced Trounson earlier this year, has tried to ...
Related articles »  
Cell transplant sees paralyzed man walk again
... embryonic stem cells used in the Geron Corporation's 2010 trial in the United States. Before that trial was stopped due to funding issues, none of the patients enrolled were able to walk.
Related articles »  
4 High-beta stocks: Ciena Corporation (NYSE:CIEN), Callaway Golf Co (NYSE ...
StemCells Inc (NASDAQ:STEM) has the market capitalization of $ 74.13M while 68.64M shares were outstanding. Beta factor, which measures the riskiness of the security, was recorded as 1.64.
Related articles »  
An in vivo model of human small intestine using pluripotent stem cells
Differentiation of human pluripotent stem cells (hPSCs) into organ-specific subtypes offers an exciting avenue for the study of embryonic development and disease processes, for pharmacologic studies and as a potential resource for therapeutic ...
Stocks in the Spotlight: StemCells(NASDAQ:STEM), Triangle Petroleum ...
StemCells Inc (NASDAQ:STEM) finished last trade at $1.19, gaining 2.15%. Trading volume recorded for this company was about 1.48M shares as compared to its average volume of 647,821.00 shares.
Medical labs' leftovers find uses elsewhere
Millions of tiny tubes of cells, proteins, antibodies, and other scientific goo sit in freezers at research institutions across the country.
RoosterBio selects BioLife Solutions CryoStor to commercialize human bone ...
Bothell-based BioLife Solutions, Inc. announced Oct. 21 that Frederick, MD based RoosterBio, Inc., has adopted the Company's CryoStor clinical grade cryopreservation freeze media to commercialize RoosterBio's human bone marrow-derived, adult ...